Background-The optimal management of atrial fibrillation remains unclear. We performed a meta-analysis of randomized controlled trials to examine the safety and the efficacy of catheter ablation (CA) when compared with antiarrhythmic drug therapy both as first-and second-line therapy for the maintenance of sinus rhythm in atrial fibrillation. Methods and Results-Several databases were searched from inception to March 2014, which yielded 11 studies with 1481 patients with atrial fibrillation. The outcomes measured were recurrence of atrial tachyarrhythmia and the incidence of adverse events. A subgroup analysis was done to evaluate the efficacy of CA as first-or second-line therapy. There was recurrence of atrial tachyarrhythmia in 222 of 785 (28%) patients who underwent CA and in 451 of 696 (65%) patients who were on antiarrhythmic drug therapy (relative risk, 0.40; 95% confidence interval, 0.31−0.52; P=0.00001). Subgroup analysis revealed a beneficial effect of CA both as a first-line (relative risk, 0.52; 95% confidence interval, 0.30−0.91; P=0.02) and as a second-line (relative risk, 0.37; 95% confidence interval, 0.29−0.48; P<0.00001) therapeutic modality. There was a significantly higher incidence of major adverse events in the CA group when compared with those in the antiarrhythmic drug therapy group (relative risk, 2.04; 95% confidence interval, 1.10-3.77; P=0.02, I 2 =0%). Conclusions-CA seems to be superior to antiarrhythmic drug therapy in drug naïve, resistant, and intolerant patients with atrial fibrillation. However, it should be performed in carefully selected patients after weighing the risks and benefits of the procedure. (Circ Arrhythm Electrophysiol. 2014;7:853-860.)
A trial fibrillation (AF) is one of the most common cardiac arrhythmias, affecting ≈2.2 million patients in the United States and 4.4 million in the European Union alone. 1 Recently, AF has emerged as a global epidemic not only because of its rising prevalence but also from an associated increase in morbidity and mortality. [2] [3] [4] AF places a great burden on society not only in regards to direct treatment costs but also in the form of lost productivity and increased disability. 5, 6 Clinical Perspective on p 860
Antiarrhythmic drug treatment (ADT) is the current standard of care for patients with paroxysmal and persistent AF according to the American Heart Association, Heart Rhythm Society and the European Society of Cardiology clinical practice guidelines. 7 Despite being the first-line therapy for AF, the efficacy and the safety of ADT remain an area of concern because of high rates of recurrence and long-term side effects. 8 Catheter ablation (CA) has been recognized as an alternative therapeutic modality in the treatment of AF. There have been several studies that have compared the role of CA and ADT for control of AF. [9] [10] [11] [12] [13] [14] [15] Meta-analyses of these studies have shown a beneficial effect of CA in preventing recurrences of AF. 16, 17 The studies included in those meta-analyses were initially proof of concept studies, mostly single-center with a small sample size. Moreover, the role of CA as a firstline therapeutic modality for AF was investigated in only 1 study. 12 On the basis of these randomized studies, we conclude that the current treatment guidelines recommend CA after failure or intolerance to ADT. 7 Nonetheless, the optimal role of CA in the management of AF remains unclear, especially in patients with paroxysmal AF who have never been exposed to ADT. With more evidence recently made available in this field, [18] [19] [20] [21] we performed a systematic review and meta-analysis to examine the safety and the efficacy of CA when compared with ADT both as first-or and second-line therapy for the maintenance of sinus rhythm in AF.
Methods

Data Sources and Search Strategy
The systematic review was performed in accordance with the preferred reporting items for systematic reviews and meta-analyses guidelines. 22 The search strategies were developed in PubMed and translated to match the subject headings and keywords for Embase, Cochrane Central Register of Controlled Trials, ISI Web of Science, and Scopus from database inception to March 14, 2014 . The following MeSH, Emtree, and keyword search terms were used in combination: atrial fibrillation, atrial tachycardia, atrial tachyarrhythmia (AT), atrial flutter, catheter ablation, radiofrequency ablation, controlled trials, intervention study and randomized controlled trials (RCT). The search accounted for plurals and variations in spelling with the use of appropriate wildcards. To identify further articles, we manually searched references and related citations. All results were downloaded into Endnote (Thompson Reuters), and duplicate citations were identified and removed.
Study Selection/Quality Assessment
Two authors (A.R.K. and S.K.) independently assessed the eligibility of the identified studies. Those chosen were RCTs that focused on the comparison of the efficacy and safety of CA to ADT in the management of AF. We included studies that used radiofrequency ablation to isolate the pulmonary veins and excluded studies that used other modalities, such as cryoablation. The methodological quality of selected studies was assessed using the Jadad scale. 23
Data Extraction
Two reviewers (A.R.K. and S.K.) independently extracted data on the year of publication, study size, patient characteristics, ablation techniques used, and relevant outcomes. The main efficacy outcome studied was recurrence of atrial arrhythmias during the follow-up period. The studies differed in the definition of a successful outcome; for example, in the ThermoCool study, 5 of the 67 patients who were defined to have procedural success with CA were still on an antiarrhythmic. However, these patients had failed the same antiarrhythmic agent before CA. 18 The studies also varied in the methods of monitoring of recurrence of AF (daily monitoring versus periodic monitoring and asymptomatic versus symptomatic recurrence). We also examined quality of life (Qol) when reported by the included trials. We did not specify a priori outcome definitions and those were accepted as defined in the individual studies.
Safety was reflected by the occurrence of adverse events. A separate analysis was performed for major adverse events, defined as sudden death, embolic events (stroke or transient ischemic attack), major bleeding, pulmonary vein stenosis, atrioesophageal fistula, pericardial complications (effusion, hemorrhage, tamponade, and perforation), and life-threatening arrhythmias.
Data Synthesis and Statistical Analysis
We performed meta-analyses on efficacy and safety of CA and ADT separately. A random-effect model was used to pool data for efficacy of CA and ADT. 24 Subgroup analysis was done to assess the efficacy of CA as first-or second-line therapy. The role of individual trials was evaluated by sensitivity analysis. Cochran Q test was used to assess heterogeneity among studies and was complemented by the I 2 statistic. 25 The role of study-level and aggregated individual-level parameters on heterogeneity was investigated by means of metaregression. The potential factors considered were number of centers (1-2 versus multicenter), mean age, percentage of men, percentage of paroxysmal AF, monitoring for recurrence (daily versus intermittent) and technique used for pulmonary vein isolation. The Mantel-Haenszel method with nonfixed zero cell correction was used to assess the safety of CA and ADT. This method is recommended whenever sparse data are pooled and the sizes of the study arms are unequal. 26 Subgroup analysis was done based on temporal period of the study (before and after 2009) to account for the improvement in technology and operator expertise. The year 2009 was chosen as the middle point of the entire period during which those trials were conducted.
Publication bias was assessed by construction of funnel plot and Begg and Mazumdar test was done to assess funnel plot asymmetry and publication bias for all the included studies. 27 Any disagreements between reviewers about the study inclusion, data extraction, and quality assessment that could not be resolved by consensus were resolved by a third reviewer (G.M.). All analyses were conducted using the statistical software Review Manager (RevMan, 5.2) and SAS software (version 9.2).
Results
The search identified 1254 publications, of which 11 studies were eligible for inclusion in the analysis (Figure 1 ). [9] [10] [11] [12] [13] [14] [15] [18] [19] [20] [21] There was excellent agreement between the reviewers about the inclusion of the studies, data abstraction, and quality assessment. The Table summarizes the characteristics of the included studies. The quality assessment of the included trials showed a score of 2 of 5 especially because of lack of blinding and because of the nature of the therapeutic interventions being compared ( Table I in the Data Supplement). There were 785 patients who underwent CA and 696 patients who were maintained on ADT. In 8 studies, CA was used in patients who had already received antiarrhythmics 9, [11] [12] [13] [14] [15] 18, 21 ; whereas in the remaining 3 trials, the patients enrolled were drug-naïve. 10, 19, 20 Most of the patients included in the studies were relatively young, had few comorbidities, normal ejection fraction, and a left atrial dimension <50 mm (Table II in the Data Supplement). Only 1 study included patients with diabetes mellitus. 15 One study included patients with only persistent AF, 12 whereas the rest of the studies enrolled patients with both paroxysmal and persistent AF. There were different methods used for pulmonary vein isolation, namely circumferential [12] [13] [14] [18] [19] [20] [21] and segmental ostial ablation. [9] [10] [11] 15 Adjunctive methods, such as linear atrial lesions and complex fractionated electrogram ablation, were used in almost all the studies dependent on investigator decision. The followup differed in the included studies being 9, 18 
Efficacy: Recurrence of Arrhythmia
There was recurrence of AT in 222 of 785 (28%) patients who underwent CA and in 451 of 696 (65%) patients who were on ADT. Our meta-analysis revealed a 60% reduction in the risk of recurrence of AT (relative risk [RR], 0.40; 95% confidence interval [CI], 0.31−0.52; P=0.00001). There was substantial between-study heterogeneity (Cochran Q test, P<0.0001; I 2 =74%; Figure 2 ). There was some suggestion of funnel asymmetry, but Begg test did not show any presence of publication bias (P=0.134; Figure 3 ). Subgroup analysis revealed recurrence of AT in 62 of 237 (26%) patients who underwent CA as a first-line therapy and in 108 of 246 (44%) patients who received ADT. Our meta-analysis revealed a 48% reduction in the risk of recurrence of AT (RR, 0.52; 95% CI, 0.30−0.91; P=0.02). There was substantial between-study heterogeneity (Cochran Q test, P<0.03; I 2 =72%; Figure 2 ).
Patients who were exposed to ADT showed a better response to CA with recurrence of AT in 160 of 548 (29%) patients who underwent CA and in 459 of 572 (80%) patients who received ADT. There was a 63% reduction in the risk of recurrence of AT (RR, 0.37; 95% CI, 0.29−0.48; P<0.00001).
There was substantial between-study heterogeneity (Cochran Q test, P<0.005; I 2 =65%; Figure 2 ).
Sensitivity analysis done to assess the effect of individual studies did not reveal a major influence of any 1 study on the pooled effect estimate, which ranged between 0.36 and 0.41. Metaregression did not reveal any significant effect of the number of centers (P=0.32), mean age (P=0.92), male sex (P=0.83), percentage of paroxysmal AF (P=0.63), technique used for pulmonary vein isolation (P=0.28), and method of monitoring recurrence (P=0.90) on the observed heterogeneity.
Efficacy: Quality of Life
Qol was reported only in 6 of the 11 included studies. It was measured by using the 36-item Short Form General health Survey in 4 studies, 11, 15, 18, 19 European Quality of Life 5 Dimension in 1 study, 20 and AF-Qol score in 1 study. 21 The studies that used 36-item Short Form General health Survey reported an improvement in Qol both in the physical (pooled mean difference, 5.0) and in the mental domains (pooled mean difference, 4.2) in the patients who underwent CA. Similar improvement was not reported in 2 recent trials, which used a different method to evaluate Qol. These results were not compared because different methods were used to assess Qol parameters.
Safety
The number of all adverse events was 70 in 785 (9%) patients who underwent CA and 77 of 696 (11%) patients who were on ADT ( Table III in the Data Supplement). There were 38 (5%) major adverse events in the CA group and 13 (2%) major adverse events in the ADT group (Table IV in the Data  Supplement) .
There was a significant difference in the incidence of major adverse events between CA and ADT (RR, 2.04; 95% CI, 1.10-3.77; P=0.02; I 2 =0%). There was a higher incidence of major adverse events in earlier studies (RR, 3.35; 95% CI, 1.15-9.75; P=0.03; I 2 =0%) when compared with those in later studies (RR, 1.51; 95% CI, 0.55-4.15; P=0.42; I 2 =27%; Figure 4 ).
Discussion
Our meta-analysis indicates that CA is associated with significant reduction in AF recurrence both as a first-and as a second-line therapy when compared with ADT. This efficacy is more apparent with previous exposure to ADT when compared with drug naïve patients. This difference was most likely driven by the efficacy of ADT to maintain sinus rhythm because the recurrence rate with CA remained unchanged whether it was used as first-or second-line therapy. Moreover, previous failure of ADT automatically selects a group of patients who have more resistant AF. 28 This may have led to selection bias with inclusion of those patients who were unlikely to respond to ADT. However, even when used in a drug naïve population, CA showed lower AF recurrence when compared with ADT.
Although the pooled analysis demonstrated the superiority of CA instead of ADT, several concerns need to be addressed before it can be widely adopted for this indication. The cumulative evidence in favor of CA was negatively influenced by heterogeneity between the studies and the safety of the procedure.
The increased use of CA is tempered by concerns during the safety of the procedure as shown by the findings of our analysis, which suggest a 2-fold increase in the incidence of major adverse events. In the studies included in our analysis, the procedure was principally performed at high-volume centers, a more widespread use by less experienced operators may lead to increased periprocedural adverse events. These concerns are not unfounded because a recent nationwide survey showed an increased incidence of complications (5.3% in 2000 to 7.5% in 2010) when performed at low-volume centers, by less experienced operators. 29 During the same time-period, the complication rate decreased from 11.1% to 1.6% in experienced hands at a single-center. 30 This finding is replicated in our analysis where more recent studies demonstrated a lower incidence of major adverse events suggestive of improved safety profile reflective of increased operator experience. This underlines the complexity of the procedure and the importance of adequate and continued training in the latest ablation techniques. This has been emphasized in the practice guidelines that recommend these procedures to be performed by an electrophysiologist with appropriate training at an experienced center. 31 It should also be kept in mind that CA is not always a curative procedure as shown by recurrence of AF in patients who underwent ablation. Multiple CA procedures may increase the cumulative risk of periprocedural complications and raises concerns during long-term effects of radiation exposure. Our findings are also likely affected by many factors ranging from technique used for ablation, ADT used, definition of outcome, and monitoring of recurrence, which may have led to the heterogeneity encountered in our analysis. The technique used for pulmonary vein isolation was different in the included studies as was the use of the adjunctive ablation methods. The use of ADT was not uniform between the trials. The studies also differed in the use of ADT in the CA arm; most studies used ADT during the blanking period (period where the antiarrhythmics were allowed after ablation), whereas in some the use of ADT varied from none in the ablation arm to comparison of ADT alone with CA and ADT. There were differences in the definition of successful outcome and time to recurrence among the studies. Moreover, the methods of monitoring these recurrences varied from daily event monitoring to periodic Holter monitoring. These likely sources of heterogeneity were investigated by means of a metaregression but were not found to be significant. Investigation of these variables would be possible only with individual patient data meta-analysis. Nevertheless, the heterogeneity would mainly affect the magnitude of the pooled estimate rather than its direction that would still favor CA.
It is unclear in most of the studies how adherence to ADT and recurrence of tachyarrhythmia was monitored in individual trials. Medication nonadherence has been known to affect treatment outcomes. The ability to crossover to the CA arm in individual trials (42%-77%) may have provided an incentive to fail medical therapy and be drug free. This may have had an effect on the results of the trials but has not been systematically evaluated.
The patients included in the majority of the trials were mostly younger, had paroxysmal AF, few comorbidities, minimal structural heart disease, left atrial diameter <50 mm, and a normal ejection fraction. Thus, our results cannot be generalized to the majority of patients with AF who may be older, have persistent AF, underlying structural heart disease, low ejection fraction, and other associated comorbidities. The effect of CA on this patient population will require further investigation.
CA has shown superiority instead of ADT using surrogate end points, and no trial has yet addressed clinical outcomes such as reduction in stroke risk and mortality. More definitive evidence on long-term outcomes will be provided by several on-going multicenter RCTs; Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial 32 and Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST) 33 designed to assess the effect of ablation on AF on the clinical end points of stroke, heart failure, hospitalization, and cardiovascular mortality. Our findings support the new updated guidelines on the role of CA in the management of AF which states "In patients with recurrent symptomatic paroxysmal AF, CA is a reasonable initial rhythm-control strategy before therapeutic trials of antiarrhythmic drug therapy, after weighing risks and outcomes of drug and ablation therapy." 34
Strengths and Limitations of Our Analysis
When compared with previous reviews, 16, 17 our analysis involves a comprehensive literature search with inclusion of the largest number of relevant studies and adds substantially to the cumulative evidence. We also have examined the potential effect of CA both as a first-or as a second-line therapy for the maintenance of sinus rhythm. The results of our analysis are weakened by limitations inherent to meta-analysis and those of the included studies. The analysis included studies that differed in the types of AF, techniques used for CA, definition for AF recurrence, time to assess recurrence, and the method of surveillance used. All these factors may have had an influence on the pooled effect estimate, which may be considered as a weakness in our analysis.
Conclusions
CA as a rhythm control strategy seems to be superior to ADT in drug naïve, resistant, and intolerant patients with AF both as a first-line and alternative therapeutic modality. CA should be done in carefully selected patients after weighing the risks and benefits of the procedure. Effects on long-term recurrence rates and hard cardiovascular outcomes remain to be elucidated.
